RongCan（Shanghai）Biotech Co., Ltd is a sino-foreign joint venture founded by renowned professors, domestic experts and overseas doctoral researchers in June 2020. RongCan Biotech focuses on the development and industrialization of nucleic acid-based therapeutics, striving to become a whole-industry-chain company that covers  from mRNA sequential design and synthesis, and LNP-based delivery systems to finished mRNA-based pharmaceutical products. As one of the few domestic R & D enterprises with special emphasis on innovative nucleic acid-based medicines, we have created proprietary RNA-based Therapeutic Platform (RTP) for development of mRNA-based vaccines and therapeutics to address unmet medical needs. 

The company’s core team, one of the leading domestic R & D teams, has been extensively involved in the market-oriented research and development of nucleic acid delivery systems for more than ten years, resulting in a patent granted by USPTO. The cationic lipid described in the granted patent has been widely used by many famous scholars from within China and abroad to deliver mRNA and siRNA therapeutics for treatment of a wide variety of diseases. Our R & D team has created proprietary ionizable lipid-like compound libraries based on which multiple LNP-based mRNA delivery systems with independent intellectual property have been developed. The developed LNP carriers allow for an efficient and targeted delivery of mRNA therapeutics to the organs of interest, such as the lungs, livers and injured vascular wall. Additionally, cell and animal studies have demonstrated their excellent biocompatibility, suggesting that they are safe for potential clinical use.